IGLV2-11: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Target Name: IGLV2-11

NCBI ID: G28816

IGLV2-11

Other Name(s): IGLV211 | V1-3 | Immunoglobulin lambda variable 2-11 | immunoglobulin lambda variable 2-11

IGLV2-11: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis and amyotrophic lateral sclerosis, are characterized by the progressive loss of nerve cells and the formation of immune-related hallmarks in the central nervous system. These diseases are often treated with immunomodulatory drugs, which aim to reduce inflammation and alleviate symptoms. However, these drugs can have a limited impact on the underlying disease mechanisms and may have potential side effects. Therefore, there is a need for new therapeutic approaches that can specifically target inflammation and promote neuro repair.

IGLV2-11: A Potential Drug Target and Biomarker

IGLV2-11 is a protein that is expressed in various tissues, including the brain, and has been shown to play a role in the development and progression of neurodegenerative diseases. IGLV2-11 has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases.

Potential Mechanisms of IGLV2-11 as a Drug Target

IGLV2-11 has been shown to contribute to the development and progression of neurodegenerative diseases by promoting the recruitment of immune cells to the site of injury or neurodegeneration. IGLV2-11 has also been shown to promote the production of pro-inflammatory cytokines, such as TNF-伪, by immune cells. These cytokines can further stimulate the recruitment of immune cells to the site of injury or neurodegeneration, leading to an persistent inflammatory response.

In addition, IGLV2-11 has been shown to promote the formation of glial cells, which are a type of immune cell that are involved in the pathogenesis of neurodegenerative diseases. The formation of glial cells is a critical event in the development of neurodegenerative diseases, as these cells are involved in the production of pro-inflammatory cytokines and in the regulation of immune cell recruitment.

Potential Use of IGLV2-11 as a Biomarker

IGLV2-11 has also been shown to be a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The production of IGLV2-11 has been shown to be affected by various factors, including the level of inflammation and the severity of neurodegeneration. Therefore, the levels of IGLV2-11 can be used as a biomarker for the diagnosis and monitoring of neurodegenerative diseases.

In addition, the levels of IGLV2-11 have been shown to be affected by various therapeutic interventions, including immunomodulatory drugs. Therefore, the levels of IGLV2-11 can also be used as a biomarker for the monitoring of the effectiveness of these therapeutic interventions.

Conclusion

IGLV2-11 is a protein that has been shown to play a role in the development and progression of neurodegenerative diseases. In addition, IGLV2-11 has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. Further research is needed to fully understand the role of IGLV2-11 in the pathogenesis of these diseases and to develop new therapeutic approaches that can specifically target IGLV2-11.

Protein Name: Immunoglobulin Lambda Variable 2-11

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV2-11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV2-11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets